Project description:Hepatic RNA from mice (C57BL/6) of 2 groups (APAP-treated (300mg/kg), n=8; APAP (300mg/kg)-AZD7986 (5mg/kg), n=8) were pooled at equal shares. Thereafter, pooled RNA underwent analysis by 3`mRNA sequencing (MACE, GenXPro, Frankfurt, Germany)
Project description:Hepatic RNA specimens from mice (C57BL/6) of the 4 groups (vehicle-treated at 24h/48h, n=6; acetaminophen (APAP)-treated (300mg/kg) at 24h/48h, n=7) were pooled at equal shares. Thereafter, pooled RNA underwent analysis by 3'mRNA sequencing (MACE, GenXPro, Frankurt, Germany).
Project description:Splenic RNA from mice (C57BL/6) of 2 groups (vehicle treated, n=5; APAP-treated (300mg/kg), n=11) were pooled at equal shares. Thereafter, pooled RNA underwent analysis by 3`mRNA sequencing (MACE, GenXPro, Frankfurt, Germany)
Project description:This SuperSeries is composed of the following subset Series:; GSE5593: Acetaminophen (APAP) Rat Blood Training Gene Expression Data Set; GSE5594: Acetaminophen (APAP) Rat Blood Test Gene Expression Data Set; GSE5595: Acetaminophen (APAP) Rat Liver Test Gene Expression Data Set; The Supplementary files (appended below) contain the mapping for the decoding of blinded samples. Experiment Overall Design: Refer to individual Series
Project description:The well-known difference in sensitivity of mice and rats to acetaminophen (APAP) liver injury has been related to differences in the fraction that is bioactivated to the reactive metabolite N-acetyl-p-benzoquinoneimine (NAPQI). Physiologically-based pharmacokinetic modelling was used to identify doses of APAP (300 and 1000 mg/kg in mice and rats, respectively) yielding similar hepatic burdens of NAPQI, to enable the comparison of temporal liver tissue responses under conditions of equivalent chemical insult.
Project description:The well-known difference in sensitivity of mice and rats to acetaminophen (APAP) liver injury has been related to differences in the fraction that is bioactivated to the reactive metabolite N-acetyl-p-benzoquinoneimine (NAPQI). Physiologically-based pharmacokinetic modelling was used to identify doses of APAP (300 and 1000 mg/kg in mice and rats, respectively) yielding similar hepatic burdens of NAPQI, to enable the comparison of temporal liver tissue responses under conditions of equivalent chemical insult.
Project description:The well-known difference in sensitivity of mice and rats to acetaminophen (APAP) liver injury has been related to differences in the fraction that is bioactivated to the reactive metabolite N-acetyl-p-benzoquinoneimine (NAPQI). Physiologically-based pharmacokinetic modelling was used to identify doses of APAP (300 and 1000 mg/kg in mice and rats, respectively) yielding similar hepatic burdens of NAPQI, to enable the comparison of temporal liver tissue responses under conditions of equivalent chemical insult.
Project description:This study aims to investigate the role of IER2 in acetaminophen (APAP)- induced liver injury. Male C57BL/6J mice were randomized to receive a single tail vein injection of either AAV8-GFP or AAV8-Ier2. Mice were fasted overnight for 14 hours followed by intraperitoneal administration of APAP (500 mg/kg). Animals were sacrificed 8 hours post-APAP challenge, and liver tissues were collected for proteomic profiling. This study aims to characterize the proteomic changes associated with IER2 overexpression during APAP hepatotoxicity, thereby establishing a foundation for subsequent mechanistic investigations.